Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

illion of H5N1 vaccine sales in the United States, against $192.5 million in the second quarter of 2008. Excluding H5N1 vaccine sales, second-quarter sales were up 18.4%. In the United States, second-quarter net sales were down by 14.5% to euro 402 million, but up 16.2% excluding H5N1 sales.

The second-quarter performance was boosted by strong growth in sales of pediatric combination vaccines. Net sales of Pentacel((R)) (the first 5-in-1 pediatric combination vaccine licensed in the United States in June 2008 against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b) reached euro 83 million for the quarter.

Net sales of seasonal influenza vaccines rose by 3.3% to euro 32 million.

In May 2009, the U.S. Food and Drug Administration licensed the new sanofi pasteur influenza vaccine manufacturing facility in Swiftwater where production of influenza vaccines has already begun. This facility, representing an investment of $150 million, will produce 100 million doses per year when operating at full capacity. It will take the Group's total production capacity in the United States to 150 million doses of trivalent seasonal influenza vaccine per year.

Sanofi Pasteur received several orders to produce a vaccine against the new A(H1N1) influenza strain, including two contracts from the U.S. Department of Health and Human Services as well as a contract from the French government. Sanofi Pasteur is in discussion with several other governments and announced last June its intent to donate 100 million doses of influenza vaccine to the World Health Organization to help developing countries face the influenza pandemic.

Net sales of Menactra((R)) (quadrivalent meningococcal meningitis vaccine) were up 2.5% at euro 110 million. Filing of Menactra((R)) Infant/Toddler 9 to 12 months in the United States is scheduled for the second half of 200
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 Oxford Finance ... debt to life sciences and healthcare services companies, today ... term loan agreement with Celula, Inc., a diagnostic testing ... diseases, enabling better patient care and improved outcomes.  Proceeds ... development and expand the commercialization of its products in ...
(Date:4/30/2015)... , April 30, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that it ... Thursday, May 7, 2015 after the close of the ... call and webcast on Thursday, May 7, 2015 at ... the results and recent corporate developments. For ...
(Date:4/30/2015)... SureClinical, a leader in cloud-based health ... joined SureClinical’s executive team as Chief Financial Officer. ... executive with over 25 years in leadership roles ranging ... Ms. Morris joins SureClinical from Marrone Bio Innovations (MBI), ... of MBI from its founding in 2006 until 2011, ...
(Date:4/29/2015)... GUELPH, ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... twelve-month periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , ... 1,191 , 1,493 , 3,377 , ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
... Study Finds Use of the Internet Now Dominates Quantitative Research ... ... out of five market research,studies -- 60 percent of those fielded in ... 2007 Medefield Pharmaceutical,Market Research Trends Study., The report, released today, indicates ...
... Year - Only Nasal Powder Bird ... - Patient-Friendly (No Needles); No Preservatives - Stable at Room Temperature For 3 ... ... Carrington,Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that its,wholly-owned subsidiary DelSite Biotechnologies, ...
... More Than 180,000 Patient Visits Each Year, East Coast,s ... Empower ... Control Over Medical Care, CEDAR KNOLLS, N.J., Feb. ... company specializing in,portable electronic medical records management solutions, today ...
Cached Biology Technology:Technology Transforms Market Research in Pharmaceutical Industry 2Technology Transforms Market Research in Pharmaceutical Industry 3Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 2Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 3Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 4Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 2Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 3Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 4
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... (Jan. 25, 2008) The American Society for Neural ... 1-3, 2008 at the Sheraton Sand Key Resort in Clearwater, ... 2008. Abstracts may be submitted electronically at www.asntr.org ... same Web site. Celebrating its 15th anniversary in 2008, the ...
... wires may hold the answer to making solar cells ... Department of Engineering Physics at McMaster University, Cleanfield Energy ... a partnership to pursue the commercialization of nanowire technology ... type of nanowire technology developed at McMaster is able ...
... Determined to revive the grossly depleted soils of ... poverty and hunger, the Alliance for a Green Revolution ... program to restore the fertility of Africas soils. ... soils where rapid nutrient loss is sapping the ability ...
Cached Biology News:ASNTR 15th anniversary meeting to be held May 1-3 in Florida 2Nanowires hold promise for more affordable solar cells 2Alliance for a Green Revolution in Africa commits 180M to revive farmers' depleted soils 2Alliance for a Green Revolution in Africa commits 180M to revive farmers' depleted soils 3Alliance for a Green Revolution in Africa commits 180M to revive farmers' depleted soils 4
... Zyagen tissue microarrays are derived from frozen ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... coated slides. Sections are large (3-5mm in ...
... Zyagen tissue microarrays are derived from frozen ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... coated slides. Sections are large (3-5mm in ...
... Engine Opticon real-time PCR detection system uses ... excitation (450-495 nm) and a photomultiplier tube ... system is built on an DNA Engine ... gradient feature. This item includes the thermal ...
... for Optimal Microdissection , CapSure HS and ... and rapid extraction of populations of pure ... with Laser Capture Microdissection., Ensure the ... Analysis , All CapSure LCM Caps have ...
Biology Products: